NetraMark’s AI to Revolutionize Clinical Trials

Netramark Holdings Inc (TSE:AIAI) has released an update.

NetraMark Holdings Inc. has entered into a contract with an undisclosed pharmaceutical company to leverage its NetraAI technology for enhancing clinical trial efficacy and reducing placebo responses. The AI-driven analytics are set to streamline the trial process by identifying key criteria, which could lead to more significant results with fewer patients, potentially accelerating the time and reducing costs for product approval. This collaboration underscores NetraMark’s role in advancing clinical research by offering actionable insights and optimizing trial designs.

For further insights into TSE:AIAI stock, check out TipRanks’ Stock Analysis page.